The Lancet Group shared a post on LinkedIn:
“In The Lancet, two separate phase 3 trials highlight potential new treatments for platinum-resistant ovarian cancer.
Platinum-resistant ovarian cancer occurs when the cancer progresses within six months of platinum-based chemotherapy. Most patients with advanced ovarian cancer eventually develop platinum-resistant ovarian cancer; treatment options are limited.”
Other articles featuring The Lancet Group on OncoDaily.